Idiopathic pulmonary fibrosis (IPF) is a chronic, fatal interstitial lung disease. Current treatment options for patients with IPF are limited, and marginally effective. Prescribed regimens vary greatly among practitioners. This study was designed to assemble a database of best available evidence from the literature regarding the efficacy and safety of the various treatments for IPF, including lung transplantation.
A systematic review of the literature from 1970 to present was performed utilizing MEDLINE (via PubMed) and Current Contents™ electronic searches as well as manual bibliography checks. Additionally, the European Respiratory Society, American Thoracic Society, and American College of Chest Physicians 2002 meetings were searched for relevant abstracts. Study and patient characteristics, treatment detail, and outcomes were extracted from accepted studies and entered into a database. Data will be synthesized across studies using descriptive statistics with stratification by covariates, and meta-analysis will be performed if data permit.
A total of 5,510 abstracts were screened for inclusion in the study set. (#) full studies and (#) meeting abstracts were included in the final analysis. A total of (#) IPF patients received medical treatment, and (#) underwent lung transplantation. Results for survival, objective and/or subjective response to treatment, reduction in concomitant treatment and/or treatment discontinuation, and quality of life outcomes will be presented.CONCLUSIONS: The results of this systematic review will quantify the efficacy of various approaches to the treatment of IPF.
This knowledge can be used in the development and testing of novel therapeutic agents and approaches in clinical trials in an effort to expand treatment options and survival for patients with this devastating disease.
K. Schoelles, InterMune, Inc., Industry.